481 related articles for article (PubMed ID: 25912412)
41. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
[TBL] [Abstract][Full Text] [Related]
42. Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study.
Scarfone G; Bergamini A; Noli S; Villa A; Cipriani S; Taccagni G; Vigano' P; Candiani M; Parazzini F; Mangili G
Gynecol Oncol; 2014 Jun; 133(3):480-4. PubMed ID: 24642093
[TBL] [Abstract][Full Text] [Related]
43. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
Lakshminarasimhan R; Andreu-Vieyra C; Lawrenson K; Duymich CE; Gayther SA; Liang G; Jones PA
Cancer Lett; 2017 Aug; 401():11-19. PubMed ID: 28483516
[TBL] [Abstract][Full Text] [Related]
44. Evidence for the Relationship Between Endometriosis and Epithelial Ovarian Cancer.
del Carmen MG
Obstet Gynecol Surv; 2015 Sep; 70(9):587-95. PubMed ID: 26403563
[TBL] [Abstract][Full Text] [Related]
45. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary.
Davis M; Rauh-Hain JA; Andrade C; Boruta DM; Schorge JO; Horowitz NS; May T; del Carmen MG
Gynecol Oncol; 2014 Mar; 132(3):760-6. PubMed ID: 24440832
[TBL] [Abstract][Full Text] [Related]
46. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Suda K; Cruz Diaz LA; Yoshihara K; Nakaoka H; Yachida N; Motoyama T; Inoue I; Enomoto T
Cancer Sci; 2020 Aug; 111(8):3000-3009. PubMed ID: 32473611
[TBL] [Abstract][Full Text] [Related]
47. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
[TBL] [Abstract][Full Text] [Related]
48. [Epigenetic inactivation of SPOCK2 in the malignant transformation of ovarian endometriosis].
Ren F; Wang DB; Li T
Zhonghua Fu Chan Ke Za Zhi; 2011 Nov; 46(11):822-5. PubMed ID: 22333230
[TBL] [Abstract][Full Text] [Related]
49. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
50. ARID1A gene mutation in ovarian and endometrial cancers (Review).
Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
[TBL] [Abstract][Full Text] [Related]
51. Pathology of Endometrioid and Clear Cell Carcinoma of the Ovary.
Fadare O; Parkash V
Surg Pathol Clin; 2019 Jun; 12(2):529-564. PubMed ID: 31097114
[TBL] [Abstract][Full Text] [Related]
52. [Risk factors of endometriosis associated ovarian carcinoma in women aged 45 years and older].
He ZX; Wang S; Li ZF; Zhu L; Leng JH; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2017 May; 52(5):314-319. PubMed ID: 28545269
[No Abstract] [Full Text] [Related]
53. [Incidence of synchronous primary neoplasms of the female reproductive tract in women with ovarian endometriosis: a retrospective analysis of 811 cases].
Grammatikakis I; Ivanov S; Evangelinakis N; Zevoudis S; Tziortzioti V
Akush Ginekol (Sofiia); 2009; 48(3):26-30. PubMed ID: 20198760
[TBL] [Abstract][Full Text] [Related]
54. CDC42-positive macrophages may prevent malignant transformation of ovarian endometriosis.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2012 May; 43(5):720-5. PubMed ID: 21944080
[TBL] [Abstract][Full Text] [Related]
55. Prognostic analysis of ovarian cancer associated with endometriosis.
Kumar S; Munkarah A; Arabi H; Bandyopadhyay S; Semaan A; Hayek K; Garg G; Morris R; Ali-Fehmi R
Am J Obstet Gynecol; 2011 Jan; 204(1):63.e1-7. PubMed ID: 21074136
[TBL] [Abstract][Full Text] [Related]
56. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary.
Kato N; Sasou S; Motoyama T
Mod Pathol; 2006 Jan; 19(1):83-9. PubMed ID: 16258507
[TBL] [Abstract][Full Text] [Related]
57. [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis].
Castiblanco G A; Pires N Y; Wistuba O I; Riquelme S E; Andrade M L; Corvalán R A
Rev Med Chil; 2006 Mar; 134(3):271-8. PubMed ID: 16676097
[TBL] [Abstract][Full Text] [Related]
58. Endometrial cancer with concomitant endometriosis is highly associated with ovarian endometrioid carcinoma: a retrospective cohort study.
Ishizaka A; Taguchi A; Tsuruga T; Maruyama M; Kawata A; Miyamoto Y; Tanikawa M; Ikemura M; Sone K; Mori M; Koga K; Ushiku T; Oda K; Osuga Y
BMC Womens Health; 2022 Aug; 22(1):332. PubMed ID: 35932070
[TBL] [Abstract][Full Text] [Related]
59. Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis.
Liu G; Xu P; Fu Z; Hua X; Liu X; Li W; Zhang M; Wu J; Wen J; Xu J; Jia X
J Cell Biochem; 2017 Dec; 118(12):4517-4525. PubMed ID: 28466574
[TBL] [Abstract][Full Text] [Related]
60. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE; Miller A; Soslow RA; Lankes HA; DeLair D; Segura S; Chavan S; Zamarin D; DeBernardo R; Moore K; Moroney J; Shahin M; Thaker PH; Wahner-Hendrickson AE; Aghajanian C
Gynecol Oncol; 2023 Sep; 176():16-24. PubMed ID: 37418832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
